Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
161. |
ECCT/17/08/05 | Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection. Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection. |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project HIV Program, Kericho |
View |
162. |
ECCT/17/08/06 | Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE) Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE) |
Principal Investigator(s) 1. Festus Muigai Njuguna Site(s) in Kenya Homa Bay County Hospital |
View |
163. |
ECCT/17/08/07 | Tambua Mapema Plus Impact of a novel HIV-1 RNA testing intervention to detect acute and prevalent HIV infection and reduce HIV transmission – Tambua Mapema Plus |
Principal Investigator(s) 1. Eduard J Sanders 2. Susan M Graham Site(s) in Kenya KEMRI Mtwapa Research Clinic |
View |
164. |
ECCT/17/08/09 | A trial to compare two new combinations of antimalarial drugs with the standard combination of antimalarial drugs in Kenyan children An open-label randomised trial to assess the therapeutic efficacy and tolerability of arterolane-piperaquine plus single low dose primaquine versus arterolane-piperaquine plus mefloquine and single low dose primaquine versus artemether-lumefantrine plus single low dose primaquine in the treatment of uncomplicated falciparum malaria in children in Kenya. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya 1. Kilifi County Hospital - Paediatric Out patient and Inpatient department (Kilifi county) 2. Pingilikani Dispensary (Kilifi county) |
View |
165. |
ECCT/17/09/01 | HPTN 084 HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
Principal Investigator(s) 1. Samuel Gurrion Ouma Site(s) in Kenya KISUMU CRS |
View |